GoAI
Get started
Rainmed Medical Limited logo

Rainmed Medical Limited

2297.HK

HKSEHealthcareMedical - Devices

Open in GoAI

Latest quote

HK$0.20

HK$0.00 · 0.00%

Aug 24, 3:48 PM HKT

2297.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Rainmed Medical Limited is a medical technology firm specializing in the creation, development, and market launch of advanced systems that utilize coronary angiography to assess fractional flow reserve (FFR) and the index of microvascular resistance (IMR). Its offerings include the FlashAngio caFFR System, which accurately determines FFR values by reconstructing a three-dimensional model of the coronary arterial system from two angiographic images. Additionally, the company provides the FlashAngio caIMR System, an innovative non-invasive solution for the diagnosis and treatment of microcirculatory lesions. Rainmed Medical is also engaged in pioneering intelligent angiographic injection technologies, robotic navigation systems for vascular interventions, and flash renal denervation solutions. Established in 2014, the company is headquartered in Suzhou, China.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CN
CEO
Yonghui Lyu
Listed since
Jul 8, 2022
Employees
210

Market position

Day range

Current HK$0.20

52-week range

Current HK$0.20

Open
HK$0.197
Previous close
HK$0.20
Volume
41K
0.12× average
Average volume
330.94K
Average daily volume
Market cap
280.27M HKD
Beta
0.58
Market reference 1
50-day average
HK$0.2254
-11.28% below average
200-day average
HK$0.2563
-21.97% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
323.73M CNY
P/E (TTM)
-3.11×
P/B (TTM)
0.67×
P/S (TTM)
12.52×
EV / EBITDA
-4.8×
Earnings yield
-24.60%
Free cash flow yield
-25.44%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
47.14%
Operating margin
-413.13%
Net margin
-401.98%
Return on equity
-21.56%
Return on assets
-14.12%
Return on invested capital
-20.67%

Financial health

Debt / equity
0.07×
Current ratio
1.13×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends255%-423%-1101%-1779%Gross margin, FY2021: 85.02%Gross margin, FY2022: 83.52%Gross margin, FY2023: 66.31%Gross margin, FY2024: 59.93%Gross margin, FY2025: 47.14%Operating margin, FY2021: -175.84%Operating margin, FY2022: -171.35%Operating margin, FY2023: -175.07%Operating margin, FY2024: -297.04%Operating margin, FY2025: -413.13%Net margin, FY2021: -780.36%Net margin, FY2022: -1609.93%Net margin, FY2023: -158.20%Net margin, FY2024: -284.99%Net margin, FY2025: -401.98%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 85.02%. Gross margin FY2022 83.52%. Gross margin FY2023 66.31%. Gross margin FY2024 59.93%. Gross margin FY2025 47.14%. Operating margin FY2021 -175.84%. Operating margin FY2022 -171.35%. Operating margin FY2023 -175.07%. Operating margin FY2024 -297.04%. Operating margin FY2025 -413.13%. Net margin FY2021 -780.36%. Net margin FY2022 -1609.93%. Net margin FY2023 -158.20%. Net margin FY2024 -284.99%. Net margin FY2025 -401.98%.

Income trends

Revenue

19.18M CNY-51.85%

Operating income

−79.22M CNY+33.03%

Net income

−77.08M CNY+32.08%
Income trends across reported periods226.56M CNY−345.27M CNY−917.09M CNY−1.49B CNYRevenue, FY2021: 81.2M CNYRevenue, FY2022: 83.6M CNYRevenue, FY2023: 73.22M CNYRevenue, FY2024: 39.82M CNYRevenue, FY2025: 19.18M CNYOperating income, FY2021: −142.78M CNYOperating income, FY2022: −143.25M CNYOperating income, FY2023: −128.18M CNYOperating income, FY2024: −118.3M CNYOperating income, FY2025: −79.22M CNYNet income, FY2021: −633.65M CNYNet income, FY2022: −1.35B CNYNet income, FY2023: −115.83M CNYNet income, FY2024: −113.5M CNYNet income, FY2025: −77.08M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 81.2M CNY. Revenue FY2022 83.6M CNY. Revenue FY2023 73.22M CNY. Revenue FY2024 39.82M CNY. Revenue FY2025 19.18M CNY. Operating income FY2021 −142.78M CNY. Operating income FY2022 −143.25M CNY. Operating income FY2023 −128.18M CNY. Operating income FY2024 −118.3M CNY. Operating income FY2025 −79.22M CNY. Net income FY2021 −633.65M CNY. Net income FY2022 −1.35B CNY. Net income FY2023 −115.83M CNY. Net income FY2024 −113.5M CNY. Net income FY2025 −77.08M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue19.18M CNY39.82M CNY73.22M CNY83.6M CNY81.2M CNY
Cost of goods sold10.14M CNY15.96M CNY24.67M CNY13.78M CNY12.17M CNY
Gross profit9.04M CNY23.87M CNY48.55M CNY69.82M CNY69.03M CNY
Research and development24.3M CNY35.44M CNY41.33M CNY44.17M CNY26.97M CNY
Selling, general, and administrative71.12M CNY97.84M CNY90.78M CNY108.09M CNY115.52M CNY
Operating expenses88.26M CNY142.16M CNY176.74M CNY213.08M CNY211.81M CNY
Interest income500K CNY3.93M CNY12.41M CNY3.5M CNY1.81M CNY
Interest expense720K CNY936K CNY1.31M CNY760K CNY3.86M CNY
Depreciation and amortization7.47M CNY16.56M CNY22.24M CNY16.66M CNY10.86M CNY
Operating income−79.22M CNY−118.3M CNY−128.18M CNY−143.25M CNY−142.78M CNY
Net income−77.08M CNY−113.5M CNY−115.83M CNY−1.35B CNY−633.65M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.06
FY2025
Latest fiscal-year revenue
19.18M CNY
FY2025 · -51.85% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.08-0.49-1.07-1.64FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend90.05M64.28M38.5M12.73MFY21FY22FY23FY24FY25

2297.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 2297.HK

research.disclaimer